Structure-based optimizations of a necroptosis inhibitor (SZM594) as novel protective agents of acute lung injury

Protective Effects of Kirenol against Lipopolysaccharide-Induced Acute Lung Injury through the Modulation of the Proinflammatory NFκB Pathway and the AMPK2-/Nrf2-Mediated HO-1/AOE Pathway

(2021) Frank Cheau-Feng Lin et al.   Antioxidants

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

(2020) Chaolin Huang et al.   LANCET

Targeting necroptosis in anticancer therapy: mechanisms and modulators

(2020) Ying Wu et al.   Acta Pharmaceutica Sinica B

Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target

(2020) Lauren Mifflin et al.   NATURE REVIEWS DRUG DISCOVERY

The role of necroptosis in cancer: A double-edged sword?

(2019) Xia Qin et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Identification of the Raf kinase inhibitor TAK‐632 and its analogues as potent inhibitors of necroptosis by targeting RIPK1 and RIPK3

(2019) Xiaofei Chen et al.   BRITISH JOURNAL OF PHARMACOLOGY

N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK-632) Analogues as Novel Necroptosis Inhibitors by Targeting Receptor-Interacting Protein Kinase 3 (RIPK3): Synthesis, Structure–Activity Relationships, and in Vivo Efficacy

(2019) Hao Zhang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeting RIPK1 for the treatment of human diseases

(2019) Alexei Degterev et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Small-Molecule Inhibitors of Necroptosis: Current Status and Perspectives

(2019) Chunlin Zhuang et al.   JOURNAL OF MEDICINAL CHEMISTRY

The potential role of necroptosis in inflammaging and aging

(2019) Gordon H. Royce et al.   GeroScience

Innate immune priming in the absence of TAK1 drives RIPK1 kinase activity–independent pyroptosis, apoptosis, necroptosis, and inflammatory disease

(2019) R.K. Subbarao Malireddi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A dominant autoinflammatory disease caused by non-cleavable variants of RIPK1

(2019) Panfeng Tao et al.   NATURE

Necroptosis in development and diseases

(2018) Bing Shan et al.   GENES & DEVELOPMENT

Necroptosis: a regulated inflammatory mode of cell death

(2018) Yogesh K. Dhuriya et al.   Journal of Neuroinflammation

Cell Death in the Lung: The Apoptosis–Necroptosis Axis

(2018) Maor Sauler et al.   Annual Review of Physiology

Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases

(2017) Philip A. Harris et al.   JOURNAL OF MEDICINAL CHEMISTRY

Receptor-interacting protein kinase 3 promotes platelet activation and thrombosis

(2017) Yiwen Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Necrostatin-1 enhances the resolution of inflammation by specifically inducing neutrophil apoptosis

(2016) Hongyu Jie et al.   Oncotarget

Necroptosis and its role in inflammation

(2015) Manolis Pasparakis et al.   NATURE

Pore-Forming Toxins Induce Macrophage Necroptosis during Acute Bacterial Pneumonia

(2015) Norberto González-Juarbe et al.   PLoS Pathogens

Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases

(2014) Holger K. Eltzschig et al.   NATURE REVIEWS DRUG DISCOVERY

TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation

(2012) S Jouan-Lanhouet et al.   CELL DEATH AND DIFFERENTIATION

The Dual Functions of Receptor Interacting Protein 1 in Fas-Induced Hepatocyte Death During Sepsis

(2011) Sam I. McNeal et al.   SHOCK

Phosphorylation-Driven Assembly of the RIP1-RIP3 Complex Regulates Programmed Necrosis and Virus-Induced Inflammation

(2009) YoungSik Cho et al.   CELL

Identification of RIP1 kinase as a specific cellular target of necrostatins

(2008) Alexei Degterev et al.   Nature Chemical Biology